Status:
COMPLETED
Effect of Ghrelin on Sympathetic Nervous System
Lead Sponsor:
Baker Heart and Diabetes Institute
Conditions:
Healthy
Obesity
Eligibility:
MALE
18-65 years
Phase:
NA
Brief Summary
Ghrelin is a newly discovered peptide that is secreted by the stomach. Its main role is to stimulate food intake but recent studies indicate that it also acts on the cardiovascular system to confer be...
Detailed Description
This study will investigate the effect of intravenous administration of ghrelin on blood pressure, heart rate, muscle sympathetic nervous activity and baroreflex control in lean and obese individuals ...
Eligibility Criteria
Inclusion
- healthy lean subjects with a BMI \< 25 kg/m2 and subjects with central obesity (according to IDF definition)
Exclusion
- any current medication
- a history of diabetes
- hypertension
- cardiovascular, cerebrovascular, liver, thyroid disease
- mental illness
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2010
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT00912587
Start Date
June 1 2009
End Date
May 1 2010
Last Update
September 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Alfred & Baker Medical Unit
Melbourne, Victoria, Australia, 3004